Indivior Strategy and Business Model

Executive Overview

Indivior is a specialty pharmaceutical company focused on treatments for opioid use disorder (OUD), overdose reversal, and selected serious mental illness indications. The Nasdaq-listed parent is Indivior PLC; “Indivior Pharmaceuticals, Inc.” is a principal U.S. operating entity. Created in 2014 through the demerger of Reckitt Benckiser’s specialty pharmaceuticals business, Indivior is headquartered in North Chesterfield, Virginia, and operates in a market where clinical evidence, payer access, controlled-substance regulation, and public-health policy all shape demand. Its portfolio is led by Sublocade, a once-monthly buprenorphine injection for OUD, alongside Suboxone Film, Perseris for schizophrenia, and Opvee for opioid overdose reversal.

Indivior’s strategy, as reflected in FY2023 reporting and 2024 investor communications, is to shift its revenue mix toward higher-growth branded specialty products, especially long-acting injectable therapies, while using a focused addiction-science pipeline and selective business development to expand beyond its legacy oral franchise. The business is heavily U.S.-weighted, with additional sales in Europe and selected international markets. For FY2023, Indivior reported net revenue of $1.09 billion.

Indivior at a Glance

Logo
Common name	Indivior
Full legal name	Indivior PLC (public parent); Indivior Pharmaceuticals, Inc. is a principal U.S. operating subsidiary
Headquarters	North Chesterfield (Richmond), Virginia, United States
Ownership	Public company
Ticker	INDV
Exchange	NASDAQ
Market Cap	$4.84B
Revenue (FY2024)	#N/A
Founding / major historical milestones	2014 demerger from Reckitt Benckiser; 2018 U.S. launches of Sublocade and Perseris; 2023 acquisition of Opiant Pharmaceuticals and FDA approval of Opvee
Industry or industries	Specialty pharmaceuticals; addiction treatment; central nervous system medicines
Key products or services	Sublocade, Suboxone Film, Perseris, Opvee
Geographic footprint	U.S.-led business with additional sales in Europe and selected international markets
Business segments as officially reported	One reportable segment; management primarily discusses performance by product and geography
Company website	https://www.indivior.com/

1. What Is the Strategy of Indivior?

Using the “Playing to Win” framework, Indivior’s strategy can be read as a focused specialty-pharma play built around leadership in addiction treatment, with selected adjacency in serious mental illness. The company is not trying to be a broad central nervous system drug company; it is concentrating resources where it believes it has distinctive credibility, know-how, and commercial access.

1a. What is the winning aspiration of Indivior?

Indivior’s public messaging centers on leadership in addiction treatment and on improving access to evidence-based care for patients with opioid use disorder and related conditions. In practical terms, “winning” means building a larger, more durable branded portfolio led by Sublocade, shifting the company away from dependence on mature oral products, and broadening its role from maintenance treatment into adjacent areas such as overdose reversal. The company has consistently framed long-acting therapies as central to better patient adherence and better clinical outcomes, so success is not just revenue growth; it is also becoming the specialist platform that prescribers, payers, and public-health stakeholders associate with serious addiction medicine.
1b. Where does Indivior play?

Indivior plays primarily in opioid use disorder, with an additional foothold in serious mental illness through Perseris and an adjacent presence in overdose rescue through Opvee. Geographically, the company plays overwhelmingly in the United States, which was the clear center of revenue and commercial focus in FY2023, while maintaining a smaller presence in Europe and other selected international markets. Customer-wise, it focuses on specialist prescribers, treatment centers, psychiatrists, public-sector accounts, and payers rather than broad primary-care consumer markets. Channel-wise, it emphasizes branded, prescription, often specialty-distributed medicines rather than high-volume commodity generics.
1c. How does Indivior plan to win?

Indivior’s plan to win is based on differentiation, not cost leadership. The core formula is to offer clinically differentiated products in high-need markets where adherence, persistence, and diversion risk matter. Sublocade embodies that approach: it is positioned as a once-monthly, healthcare-provider-administered buprenorphine therapy that can reduce some of the frictions associated with daily dosing. Public company materials in 2023 and 2024 also suggest a second leg of the strategy: use focused business development, such as the Opiant acquisition, to add adjacent assets that fit the addiction-treatment platform. Indivior then supports those products with market-access work, field education, public-sector engagement, and patient-support capabilities. The company is effectively trying to build a narrow but defensible specialty platform rather than a broad pharma portfolio.
1d. What capabilities must Indivior have in place?

To make that strategy work, Indivior needs strong capabilities in addiction-focused clinical development, regulatory execution, reimbursement and payer access, specialty commercialization, drug-safety monitoring, and controlled-substance manufacturing oversight. It also needs the ability to support physician-administered and specialty-distributed products, which requires more than traditional retail prescription selling. Because the company depends heavily on a small number of key brands, it also needs disciplined lifecycle management, dependable external manufacturing relationships, and selective business-development judgment.
1e. What management systems does Indivior require?

Indivior needs management systems that track product-level growth, prescriber adoption, patient persistence, access wins, channel inventory, product quality, and compliance. In a business built around controlled substances and highly regulated promotion, medical, legal, regulatory, and quality systems are not support functions; they are part of the operating core. The company also needs capital-allocation discipline, because a focused portfolio means that decisions on commercial spending, pipeline funding, and business development have outsized impact. Finally, it needs integrated sales and operations planning across internal teams, contract manufacturers, and specialty distribution channels so that growth in products such as Sublocade does not outrun supply reliability.

2. What Are the Current Strategic Initiatives of Indivior?

Based on FY2023 reporting and 2024 investor communications, Indivior’s current strategic initiatives are relatively clear and tightly linked to a small number of value drivers.

Scale Sublocade further in U.S. opioid use disorder treatment. This is the central commercial initiative. Management has emphasized expanding the prescriber base, increasing use across treatment settings, and improving patient initiation and persistence. A key enabler was the late-2023 U.S. label update supporting more rapid treatment initiation, which reduces onboarding friction and potentially broadens site-of-care adoption.
Expand payer access and operational ease of use. For a provider-administered OUD medicine, winning requires more than clinical demand. Indivior has to improve reimbursement, streamline site-of-care workflows, and convince treatment systems that the economics and logistics are manageable.
Commercialize Opvee. After FDA approval in 2023, Opvee became an important new growth initiative. Its likely commercial emphasis is on public-interest and public-health channels such as first responders, hospitals, universities, community programs, and other institutions concerned with synthetic-opioid overdose risk.
Manage the legacy oral franchise for cash and continuity. Suboxone Film remains important, but it is no longer the growth engine. The strategic task is to maximize value from a mature brand while managing generic pressure and channel dynamics.
Advance a focused addiction-science pipeline. Indivior has continued to present itself as a targeted innovator in addiction medicine, using internal development, partnerships, and selective acquisitions rather than trying to replicate the breadth of a large pharmaceutical company.
Grow Perseris selectively. Perseris is smaller than the OUD franchise, but it gives Indivior a commercial presence in schizophrenia and long-acting injectable psychiatry. The strategic emphasis appears selective rather than all-in.

3. What Is the Business Model of Indivior?

Indivior’s business model is that of a focused branded specialty-pharmaceutical company. Customers do not buy a software subscription or a device ecosystem; they buy prescription medicines with clinically differentiated profiles, supported by reimbursement work, medical education, and specialty distribution.

What customers actually buy: branded OUD, schizophrenia, and overdose-reversal therapies prescribed by clinicians and reimbursed by government and commercial payers.
Recurring versus one-time revenue: much of the model is repeat-driven because OUD and schizophrenia are chronic conditions. Sublocade and Perseris are monthly therapies; Suboxone Film can be refill-driven. Opvee is more episodic and may include institutional or public-health purchases.
How pricing power works: Indivior has some pricing leverage where products are clinically differentiated, but that leverage is constrained by payer formularies, rebates, public reimbursement rules, and substitutes such as generic buprenorphine/naloxone or competing long-acting products.
Why business mix matters: the economics of a growth brand such as Sublocade are very different from those of a mature oral product under generic pressure. As the mix shifts toward higher-value specialty products, the company’s growth profile and margin quality can improve.
What drives gross margin and operating margin: product mix, net pricing after rebates and discounts, manufacturing yields, supply reliability, field-force productivity, and R&D intensity. A greater share of revenue from differentiated branded injectables generally helps margin quality more than a mix dominated by mature oral products.
What drives cash generation: cash comes from branded-drug economics with relatively modest capital expenditure needs compared with heavy manufacturing industries. The main cash demands are commercial investment, R&D, legal and compliance costs, and working capital tied to inventories and receivables.
Revenue model: traditional pharmaceutical product sales through wholesalers, specialty distributors, specialty pharmacies, and other institutional channels. It is a prescription-drug revenue model, not a subscription or usage-based software model.

4. What Products and/or Services Does Indivior Sell?

Indivior sells a relatively concentrated portfolio of branded prescription medicines. That concentration is strategically important because a small number of products account for most of the business’s economic value.

Sublocade is the company’s most important growth product. It is a once-monthly extended-release buprenorphine injection for moderate to severe opioid use disorder and is the strategic centerpiece of the portfolio.
Suboxone Film is a mature but still significant product for opioid use disorder. It helped define Indivior historically, but it now sits in a more competitive, generic-exposed part of the market.
Perseris is a once-monthly extended-release risperidone product for schizophrenia. It is materially smaller than the OUD franchise, but it gives Indivior a presence in long-acting psychiatric treatment.
Opvee is nalmefene nasal spray for opioid overdose reversal. It extends Indivior into overdose response, a logical adjacency to the company’s addiction-treatment focus.
Legacy and smaller products include other lower-scale or market-specific offerings that are strategically less important than the four brands above.

From a revenue and strategic standpoint, Sublocade appears to be the most important asset, while Suboxone Film remains an important cash generator in a mature category. Perseris and Opvee are smaller but strategically useful because they broaden the company’s presence beyond a single-product story.

5. What Are the Key Competitors or Peers of Indivior?

Indivior competes product by product rather than across a broad diversified-pharma portfolio. Its most relevant competitors differ by therapeutic area.

Camurus / Braeburn — The Buvidal/Brixadi franchise is among the closest direct competitors to Sublocade in long-acting buprenorphine treatment for opioid use disorder.
Alkermes — Vivitrol is a monthly injectable naltrexone product used in opioid and alcohol dependence. It is a substitute therapy rather than a direct buprenorphine equivalent.
Orexo — Zubsolv competes in transmucosal buprenorphine/naloxone treatment for opioid dependence and is relevant particularly against Suboxone Film.
Generic buprenorphine/naloxone manufacturers, including Dr. Reddy’s and Alvogen — These are lower-priced substitutes that pressure the mature oral OUD franchise.
Emergent BioSolutions — Narcan nasal spray is the most visible branded competitor to Opvee in opioid overdose reversal.
Johnson & Johnson (Janssen) — The Invega long-acting injectable franchise competes for psychiatrist attention, payer access, and schizophrenia-treatment budgets.
Otsuka — Its long-acting antipsychotic products are relevant peers in the serious mental illness market where Perseris competes.
Teva — Uzedy is a long-acting risperidone product and is a more direct competitive reference point for Perseris.

The main strategic point is that Indivior’s strongest competitive battles are in long-acting OUD treatment, where differentiation and access matter, and in mature oral OUD, where generic pressure matters much more.

6. What Is the Marketing Strategy of Indivior?

Indivior’s marketing strategy is primarily a specialty-pharma, account-based model rather than a consumer-brand model. The company’s products sit in highly regulated therapeutic areas where clinical education, reimbursement support, and institutional access often matter more than broad mass advertising.

For Sublocade, marketing appears to center on physician and treatment-center education, payer and policy engagement, patient-support messaging, and evidence-based claims around adherence and treatment continuity. Because OUD treatment is influenced by stigma, workflow barriers, and reimbursement complexity, Indivior’s marketing has to help change provider behavior, not simply build awareness.

For Opvee, the marketing emphasis is likely even more channel-specific: public-health buyers, hospitals, emergency-response settings, and institutions concerned with synthetic-opioid overdoses. For Perseris, the strategy is closer to classic specialty psychiatry marketing, with field calls on psychiatric prescribers and formulary work.

Overall, marketing is important to Indivior, but it is not the sole differentiator. Clinical positioning, payer access, and field execution are more central to performance than brand advertising alone.

7. What Are the Key Customer Segments of Indivior?

Indivior serves several overlapping customer groups, and the economic buyer is often different from the prescribing clinician.

Addiction-treatment providers and prescribers — Office-based OUD prescribers, treatment centers, psychiatrists, and community clinics are central to adoption of Sublocade and legacy OUD products.
Psychiatry providers — Psychiatrists and psychiatric practices matter for Perseris.
Payers — Medicaid programs, commercial insurers, pharmacy benefit managers, and government systems are critical because reimbursement strongly shapes access and utilization.
Public-sector institutions — Veterans Affairs, correctional-health systems, justice-system programs, and state or local public-health agencies are especially important in addiction treatment.
Hospitals, emergency-response organizations, and public-health purchasers — These are likely important early-channel customers for Opvee.
Wholesalers, specialty distributors, and specialty pharmacies — These are direct purchasing intermediaries even when the end-use decision is made by clinicians and payers.
Patients — Patients are the end beneficiaries and influence persistence and adherence, but they are not usually the direct invoiced customer.

The business is not broadly diversified across dozens of unrelated end markets. It is meaningfully concentrated in U.S. addiction treatment, which creates focus but also concentration risk.

8. What Is the Sales Model of Indivior?

Indivior uses a specialty-pharma sales model that combines indirect product distribution with direct commercial influence. The company typically sells into the channel through wholesalers, specialty distributors, specialty pharmacies, and institutional buyers, while its own field teams work directly with prescribers, treatment systems, and payers to drive adoption.

Direct field selling: representatives and account managers call on addiction specialists, treatment centers, psychiatrists, and institutional accounts.
Payer and market-access selling: dedicated teams work on formulary placement, reimbursement pathways, and utilization-management barriers.
Specialty distribution: products such as Sublocade require a more managed channel than a typical oral retail prescription, which makes operational support and account management especially important.
Public-sector and institutional channels: correctional systems, hospitals, and public-health agencies require account-based selling and procurement support rather than traditional retail pull.
International partner/distributor model: outside the core U.S. market, Indivior often relies more on local partners and distributors.

This channel structure matters strategically because growth depends on more than prescription demand. The company has to solve site-of-care workflow, reimbursement, and logistics issues. That makes sales execution more operationally complex than standard retail-pharmacy pharma selling.

9. In What Geographies Does Indivior Operate?

Indivior operates globally, but it is not geographically balanced. As of FY2023, the United States was by far the company’s most important market commercially and strategically. That is where its largest products, payer relationships, and growth initiatives are concentrated.

Operationally, Indivior is headquartered in North Chesterfield, Virginia and maintains U.K. operations, including manufacturing and corporate infrastructure inherited from its historical roots. It also sells into selected European and other international markets through a mix of direct activity and partners or distributors.

The practical implication is that Indivior should be viewed as a U.S.-led specialty pharmaceutical company with supplemental international business, not as a globally diversified large-cap pharma company. That geographic concentration gives management focus, but it also increases exposure to U.S. reimbursement, regulation, litigation, and competitive dynamics.

10. Who Are the Owners of Indivior?

Indivior is a publicly traded company. As of 2024 public disclosures, it did not appear to have a controlling shareholder, and ownership was broadly institutional, which is typical for a mid-cap listed pharmaceutical company. Because shareholder positions change over time, the most reliable source for current large holders is the company’s latest proxy materials and regulatory filings.

11. How Is Indivior Organized?

At a practical level, Indivior is organized more simply than a diversified pharmaceutical company. The legal parent is Indivior PLC, with operating subsidiaries in the United States and other jurisdictions. For external reporting, the company has described itself as having one reportable segment, which reflects the concentrated nature of the business.

Managerially, the company appears to be organized around a product-and-function model:

Commercial teams focused on OUD, psychiatry, payer access, and institutional channels.
Research and development focused on addiction science and selected adjacent central nervous system opportunities.
Technical operations and supply covering manufacturing oversight, quality, procurement, and distribution.
Medical, regulatory, and safety functions that are critical in a tightly regulated therapeutic area.
Corporate functions such as finance, legal, compliance, and business development.

This structure supports focus, but it also means portfolio concentration matters: a small number of products can have outsized impact on the whole organization.

12. How Does Indivior Operate?

Indivior’s day-to-day operation is a combination of pharmaceutical development, regulated supply management, specialty commercialization, and payer access execution. The company creates value by taking clinically differentiated central nervous system products from development or acquisition through regulatory approval, manufacturing, distribution, and ongoing commercialization.

Operationally, the workflow looks roughly like this:

Develop or acquire a product that fits the addiction-treatment or adjacent CNS focus.
Manage regulatory approvals, medical affairs, and drug-safety requirements.
Source active ingredients and finished-product manufacturing through internal capabilities and third-party partners.
Release product through validated quality systems and distribute it through wholesalers, specialty channels, or institutional channels.
Secure reimbursement and support provider workflows, especially for specialty-administered products such as Sublocade.
Use field teams, account managers, and public-sector engagement to drive adoption.
Monitor safety, compliance, channel inventory, and real-world usage.

The main operational complexities are predictable: controlled-substance regulation, supply reliability, payer access, site-of-care logistics for injectable products, and the need to support clinicians working in often under-resourced addiction-treatment settings.

13. What Are the Growth Opportunities for Indivior?

Based on management commentary in 2023 and 2024 and on reasonable external synthesis, Indivior’s most plausible growth opportunities are concentrated rather than broad.

Deeper penetration of long-acting OUD treatment in the U.S. This is the clearest opportunity. OUD remains underdiagnosed and undertreated, and long-acting therapies still have room to expand across clinics, health systems, and public-sector programs.
Use of the updated Sublocade initiation approach to widen adoption. Reducing treatment-start friction can improve conversion and make the product more practical in more care settings.
Expansion in correctional, justice-system, and public-sector channels. These settings are strategically important in OUD because relapse and overdose risk can be especially acute around transitions of care.
Scaling Opvee. The overdose-rescue market is crowded, but concern about synthetic opioids creates an opening for differentiated public-health positioning.
Selective international growth. Indivior is U.S.-centric, so even measured expansion in selected non-U.S. markets could add diversification if products and reimbursement pathways support it.
Pipeline and business-development expansion. The company can grow by adding assets that fit addiction medicine and adjacent CNS treatment, especially where its existing field and payer capabilities are relevant.
Better portfolio mix. Even without major new products, a continued shift toward higher-growth branded specialty therapies can improve the quality of revenue and earnings.

The main constraints are also clear: payer access friction, stigma and limited provider capacity in addiction treatment, product concentration, manufacturing and quality risk, generic pressure on legacy products, and competition from other long-acting therapies and overdose-rescue products.

14. What Is the History of Indivior?

2014: Indivior was created through the demerger of Reckitt Benckiser’s specialty pharmaceuticals business, giving it an independent public-company identity focused on addiction treatment.
2018: The launches of Sublocade and Perseris marked an important strategic shift toward long-acting injectable specialty products and away from reliance on oral legacy products alone.
2019-2020: The company went through significant legal and regulatory scrutiny related to historic Suboxone marketing practices, culminating in major U.S. settlements in 2020. Those events were important because they affected capital allocation, governance attention, and the company’s public profile.
2023: Indivior acquired Opiant Pharmaceuticals, adding overdose-rescue and pipeline assets aligned with the addiction focus. In the same year, the FDA approved Opvee.
2023-2024: Indivior increased its U.S. capital-markets orientation, including a Nasdaq listing and, in 2024, an announced plan to cancel its London listing and concentrate trading in the United States. That announcement reflected where its investor base, management focus, and commercial center of gravity had moved.

15. What Are the Key Suppliers to Indivior?

Suppliers matter to Indivior because it operates in a tightly regulated pharmaceutical supply chain and relies on both internal oversight and third-party manufacturing capabilities. Public filings have emphasized dependence on external manufacturers and service providers for parts of the portfolio, even if specific supplier names are not always prominently disclosed.

Active pharmaceutical ingredient suppliers for key molecules such as buprenorphine, naloxone, risperidone, and nalmefene.
Contract manufacturing organizations for formulation, sterile fill-finish, packaging, and finished-dose production.
Packaging and device suppliers for products such as nasal-spray and injectable formats.
Specialty logistics and cold-chain providers where temperature control and chain-of-custody matter.
Third-party logistics and distribution partners that move product into specialty and institutional channels.

Supplier structure matters strategically because a single quality issue, capacity bottleneck, or regulatory observation at a critical external manufacturer can disrupt revenue in a concentrated portfolio.

16. What Are the Key Brands Owned by Indivior?

Brands matter at Indivior, but in a pharmaceutical context their strength comes from clinical evidence, access, and prescriber trust more than from consumer-style advertising.

Sublocade — Indivior’s flagship growth brand, positioned around once-monthly buprenorphine treatment for opioid use disorder and the practical benefits of long-acting therapy.
Suboxone — The company’s legacy anchor brand in OUD treatment. It remains well known, but it now operates in a more mature and generic-exposed market.
Perseris — A branded once-monthly risperidone product for schizophrenia, positioned in long-acting psychiatry.
Opvee — A newer brand in opioid overdose reversal, positioned around nalmefene-based rescue in a market shaped by synthetic-opioid concerns.

Among these, Sublocade is the most strategically important brand today, because it best represents the company’s desired future mix and differentiation.

17. How Does the Supply Chain of Indivior Function?

Indivior’s supply chain is more complex than a simple tablet business because its portfolio spans films, injectable products, and nasal-spray formats, each with different manufacturing and channel requirements.

Sourcing: procure active ingredients, excipients, packaging components, and device elements through qualified suppliers.
Manufacturing: use internal capabilities and contract manufacturers for formulation, fill-finish, packaging, and release under pharmaceutical quality standards.
Quality release: each batch must pass stringent testing and documentation requirements, which is especially important in controlled-substance categories.
Distribution: ship through wholesalers, specialty distributors, specialty pharmacies, and institutional channels, depending on the product.
Site-of-care support: for products such as Sublocade and Perseris, supply-chain execution has to align with provider administration, inventory practices, and reimbursement timing.
Public-sector logistics: for Opvee, supply may need to reach hospitals, emergency-response organizations, and community or government programs.

Supply-chain reliability is strategically important because treatment disruption in OUD can have direct clinical consequences, while stock-outs or launch friction can slow commercial adoption of newer products.

18. What Are the Key Assets of Indivior?

Indivior’s most important assets are a mix of intangible pharmaceutical assets and specialized operating capabilities rather than heavy industrial infrastructure alone.

Regulatory approvals for Sublocade, Suboxone Film, Perseris, and Opvee.
Formulation know-how and intellectual property around delivery systems and branded product differentiation.
Commercial relationships with prescribers, treatment centers, payers, and public-sector accounts in addiction medicine.
Addiction-treatment expertise built over years of operating in OUD markets.
Manufacturing and supply network that can support regulated specialty products.
Pipeline rights and acquired assets added through business development, including assets obtained through the Opiant transaction.

Like many pharmaceutical companies, Indivior’s economic moat is more intangible than physical. The critical assets are approvals, relationships, formulations, and focused domain expertise.

19. What Is the R&D Strategy of Indivior?

R&D is important to Indivior, but the company’s approach is focused rather than broad. Its research strategy is to concentrate on addiction science and selected adjacent central nervous system conditions where it believes its commercial platform and clinical credibility give it an advantage.

Public disclosures in 2023 and 2024 point to three broad R&D themes:

Lifecycle management of existing core assets, especially where label changes or differentiated clinical positioning can improve adoption.
Targeted pipeline investment in substance-use disorders and related conditions, rather than a sprawling discovery portfolio across many therapeutic areas.
Use of business development to supplement internal R&D, as seen with Opiant and other external innovation sources.

This is a rational strategy for a company of Indivior’s scale. It cannot outspend large pharmaceutical companies across a wide research base, so it is better served by deep focus in a few areas where unmet need is high and commercialization can leverage existing relationships.

20. What Major Acquisitions Has Indivior Made?

Indivior has not historically operated as a high-volume serial acquirer. Its M&A approach appears selective and capability-driven rather than roll-up oriented.

The most important recent acquisition was Opiant Pharmaceuticals, completed in 2023. Strategically, that deal mattered because it added Opvee, an approved overdose-reversal product, and other pipeline assets aligned with addiction treatment and overdose response. In other words, the acquisition was not diversification for its own sake; it was an adjacency move that broadened Indivior’s role within the same public-health ecosystem.

The broader pattern is that Indivior seems more likely to use selective acquisitions, licensing, and partnerships to add innovation than to pursue large-scale portfolio reshaping.

21. How Companies Like Indivior Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Indivior use Umbrex when they need top-tier problem-solving in strategy, operations, organization, marketing, sales, finance, technology, ERP, or AI, but do not need a full consulting team with large-firm overhead. For a focused specialty-pharma company such as Indivior, the most useful projects are usually tightly scoped, high-impact initiatives linked to growth brands, access, supply, and portfolio focus.

Sublocade growth strategy: prioritize the highest-value treatment settings, geographies, and account types for the next wave of U.S. expansion.
Payer access and reimbursement improvement: identify where formulary wins, utilization-management simplification, or provider workflow changes could unlock faster product adoption.
Opvee launch acceleration: design channel strategy for hospitals, universities, public-health agencies, emergency responders, and community programs.
Sales force effectiveness: redesign territories, call plans, account segmentation, and key-account coverage for addiction and psychiatry field teams.
Provider journey redesign: map the patient and clinic workflow for initiation, procurement, administration, and reimbursement of provider-administered products, then remove friction points.
Supply-chain resilience assessment: evaluate contract-manufacturing concentration, inventory policies, and contingency planning for key brands.
International market prioritization: assess which ex-U.S. markets offer the best balance of reimbursement feasibility, regulatory pathway, and commercial return.
Portfolio and R&D prioritization: help management compare internal programs, licensing opportunities, and bolt-on acquisitions within addiction and adjacent CNS categories.
Post-acquisition integration support: integrate acquired assets, teams, and operating processes after transactions such as Opiant.
Public-sector growth strategy: build targeted go-to-market plans for correctional health, Veterans Affairs, state programs, and other government-linked channels where OUD treatment demand is significant.